News
Melbourne biotech Mesoblast (ASX:MSB) is attempting to commercialise a stem cell treatment known as remestemcel-L for conditions such as acute graft versus host disease, advanced heart failure and chronic lower back pain due to degenerative disc disease. Mesoblast acquired remestemcel-L from US-based Osiris Therapeutics in 2013.
Mesoblast’s proprietary process selects precursors and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell bank is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5 billion in 2011. The company dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The company was dealt a blow in October 2020 when the US Food and Drug Administration declined to approve remestemcel-L for the treatment of acute graft versus host disease in children, instead asking for more data. Mesoblast is expected to dispute the FDA’s decision.
Mesoblast licensed remestemcel-L to Swiss pharmaceutical giant Novartis in November 2020 for indications other than graft versus host disease, a devastating complication from bone marrow transplants.
RELATED STOCKHEAD STORIES
News
ASX stocks in America: Opthea’s about to join the ranks but who’s there already?
Health & Biotech
Mesoblast has treated dozens of COVID-19 patients with its remestemcel-L drug
News
Hot Money Monday: These are the most in-demand stocks on the ASX right now
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Wake me up when September ends
Health & Biotech
Mesoblast plunges after US FDA requires new trial
News
10 at 10: These ASX stocks are riding like the wind this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Mesoblast now expects to release Ryoncil ruling on Monday
Health & Biotech
Crucial period for Mesoblast as key FDA ruling looms
Health & Biotech
Cynata stem cell technology a triumph: scientist
Health & Biotech
Mesoblast’s potential Covid-19 treatment wins industry award
Experts
ScoPo’s health powerplays: Pot stocks get a boost
Experts
Scopo’s Health Powerplays: Show me the (grant) money
Health & Biotech
Check up: Health sector slips as earning season ends
Health & Biotech